David Sponsel Sells 12,946 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 12,946 shares of Alphatec stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $10.73, for a total transaction of $138,910.58. Following the completion of the sale, the executive vice president now owns 722,128 shares of the company’s stock, valued at $7,748,433.44. This represents a 1.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

David Sponsel also recently made the following trade(s):

• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The stock was sold at an average price of $11.42, for a total transaction of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total value of $2,380.00.

Alphatec Price Performance

NASDAQ ATEC opened at $12.12 on Friday. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $15.01. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -9.47 and a beta of 1.43. The company’s 50 day moving average is $10.57 and its two-hundred day moving average is $8.35.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The firm had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. As a group, research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Hedge Funds Weigh In On Alphatec

Several large investors have recently made changes to their positions in the business. Lido Advisors LLC grew its position in shares of Alphatec by 8.4% during the fourth quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company’s stock worth $112,000 after purchasing an additional 953 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Alphatec by 0.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock worth $2,873,000 after purchasing an additional 1,120 shares during the period. Comerica Bank grew its holdings in Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after buying an additional 1,248 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in Alphatec by 14.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company’s stock valued at $100,000 after buying an additional 1,342 shares in the last quarter. Finally, Atria Investments Inc raised its position in shares of Alphatec by 8.0% during the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after buying an additional 1,460 shares during the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on ATEC shares. Piper Sandler increased their target price on Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price objective on shares of Alphatec in a research note on Thursday. Barclays boosted their target price on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.